Realism in evidence based medicine: Interpreting the randomised controlled trial

Journal of Health Organization and Management

Volumn 18, Issue 2, 2004, Pages 70-81

  Connelly, Jim ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Medicines; Research; Trials

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EMPIRICAL RESEARCH; EMPIRICISM; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; HUMAN; OBSERVATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL ANALYSIS; STATISTICS;

CAUSALITY; DATA INTERPRETATION, STATISTICAL; EMPIRICAL RESEARCH; EMPIRICISM; EVIDENCE-BASED MEDICINE; HUMANS; OBSERVATION; RANDOMIZED CONTROLLED TRIALS;

EID: 5444274572     PISSN: 14777266     EISSN: None     Source Type: Journal    
DOI: 10.1108/14777260410538861     Document Type: Article

References (36)

1. Altman, D.G. (1991), Practical Statistics for Medical Research, Churchill Livingstone, London.
2. Bellomo, G. (1999), “Is it really time to perform large intervention trials with antioxidant vitamins to prevent cardiovascular disease?”, Pharmacological Research, Vol. 40 No. 3, pp. 207-8.
3. Bhaskar, R. (1994), Plato etc., Verso, London.
4. Boaz, M., Smetana, S., Weinstein, T., Matas, Z., Gafter, U. and Iaina, A. (2000), “Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial”, Lancet, Vol. 356 No. 9237, pp. 1213-8.
5. Cameron, D. and Jones, I.G. (1982), “Theory in community medicine”, Community Medicine, Vol. 47, pp. 3-11.
6. Cameron, D. and Jones, I.G. (1983), “John Snow, the Broad Street pimp and modern epidemiology”, International Journal of Epidemiology, Vol. 12 No. 4, pp. 393-6.
7. Chalmers, T.C. (1995), “Antioxidants and cardiovascular disease: why do we still not have the answers”, Annals of Internal Medicine, Vol. 123 No. 11, p. 887.
8. Chalmers, T.C. (1999), What Is this Thing Called Science?, 3rd ed., Open University Press, Buckingham.
9. Connelly, J. (2000), “A realist theory of health sector management: the case for critical realism”, Journal of Management in Medicine, Vol. 14, pp. 262-71.
10. Connelly, J. (2001), “Critical realism and health promotion: effective practice needs an effective theory”, Health Education Research, Vol. 16 No. 2, pp. 115-9.
11. Connelly, J. (2002), “The behaviour change consortium studies: missed opportunities – individual focus with an inadequate engagement with personhood and socio-economic realities”, Health Education Research, Vol. 17 No. 6, pp. 691-5.
12. Curb, J.D., Borhani, N.O., Schnaper, H., Kass, E., Entwisle, G. and Williams, W. (1985), “Detection and treatment of hypertension in older individuals”, American Journal of Epidemiology, Vol. 121 No. 3, pp. 371-6.
13. Fisher, L.D. (1999), “Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA pradigm and reflections on hypothesis testing”, Controlled Clinical Trials, Vol. 20 No. 1, pp. 16-39.
14. Freemantle, N. (2001), “Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?”, British Medical Journal, Vol. 322 No. 7292, pp. 989-91.
15. Guyatt, G.H., Sackett, D.L. and Cook, D.J. (1994), “Users' guides to the medical literature, II: how to use an article about therapy or prevention. B: what were the results and will they help me in caring for my patients?”, JAMA, Vol. 271 No. 1, pp. 59-63.
16. Heart Protection Study Collaborative Group (2002), “MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial”, Lancet, Vol. 360 No. 9326, pp. 23-33.
17. Hempel, C.G. (1966), Philosophy of Natural Science, Prentice Hall, Englewood Cliffs, NJ.
18. Higgins, J., Thompson, S., Deeks, J. and Altman, D. (2002), “Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice”, Journal of Health Services Research and Policy, Vol. 7 No. 1, pp. 51-61.
19. Hopayian, K. (2001), “The need for caution in interpreting high quality systematic reviews”, British Medical Journal, Vol. 323 No. 7314, pp. 681-4.
20. Hume, D. (1995), A Treatise of Human Nature, Oxford University Press, Oxford.
21. Jadad, A., Cook, D.J. and Brownman, G.P. (1997), “A guide to interpreting discordant systematic reviews”, Canadian Medical Association Journal, Vol. 156 No. 10, pp. 1411-6.
22. Li, J.Z.Q. and Egger, M. (2001), Intravenous Magnesium for Acute Myocardial Infarction (Protocol for a Cochrane Review), The Cochrane Library, Update Software, Issue 2, Oxford.
23. Links, M. and Brown, R. (1999), “Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs”, Expert Reviews in Molecular Medicine, available at: www.ermm.cbcu.cam.ac.uk (txt 001rbg), (accessed October 2002).
24. MAGIC Steering Committee (2000), “Rational and design of the magnesium in coronaries (MAGIC) study: a clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction”, American Heart Journal, Vol. 139 No. 1, pp. 10-14.
25. Messerli, F.H. and Grossman, E. (1999), “Beta-blockers and diuretics: to use or not to use”, American Journal of Hypertension, Vol. 12 No. 12, pp. S157-S163.
26. MRC Working Party (1992), “Medical research council trial of treatment of hypertension in older adults: principal results”, British Medical Journal, Vol. 304 No. 6824, pp. 405-12.
27. Muir Grey, J.A. (1997), Evidence-based healthcare, Churchill Livingstone, London.
28. Mulrow, C., Lau, J., Cornell, J. and Brand, M. (2001), Pharmacotherapy for Hypertension in the Elderly (Cochrane Review), The Cochrane Library, Update Software, Issue 2, Oxford.
29. Norris, C. (1997), Against Relativism, Blackwell, London.
30. Packer, M., O'Connor, C.M., Ghali, J.K., Pressler, M.L., Carson, P.E. and Belkin, R.N. (1996), “Effect of amlodipine on morbidity and mortality in severe chronic heart failure”, The New England Journal of Medicine, Vol. 335 No. 15, pp. 1107-14.
31. Pawson, R. and Tilley, N. (1997), Realistic Evaluation, Sage, London.
32. Pocock, S.J. and Elbourne, D.R. (2000), “Randomized trials or observational tribulations?”, The New England Journal of Medicine, Vol. 342 No. 25, pp. 1907-9.
33. Steinberg, D. (1995), “Clinical trials of antioxidants in atherosclerosis: are we doing the right thing?”, Lancet, Vol. 346 No. 8966, pp. 36-8.
34. Stevens, A. and Milne, R. (1997), “The effectiveness revolution and public health”, in Ed. Scally, G. (Ed.), Progress in Public Health, FT Healthcare, London.
35. Thackray, S., Witte, K., Clark, A.L. and Cleland, J.G.F. (2000), “Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT”, European Journal of Heart Failure, Vol. 2, pp. 209-12.
36. Thompson, S.G. and Higgins, J.P.T. (2002), “How should meta-regression analyses be undertaken and interpreted?”, Statistics in Medicine, Vol. 21, pp. 1559-73.